Profiles of Leading Women Scientists on AcademiaNet.
Search among the members of the Leopoldina for experts in specific fields or research topics.
Image: private
Nobel Prize in Physiology or Medicine 2018
Year of election: | 2003 |
Section: | Microbiology and Immunology |
City: | Kyoto |
Country: | Japan |
Research Priorities: Molecular biological causes of antibody diversity, immunological approaches to cancer therapy, checkpoint inhibitors
Tasuku Honjo is a physician who researches the molecular biological mechanisms of immune responses. His work has contributed to the understanding of important processes in the maturation of B-lymphocytes, which produce antibodies. Point mutations and class switching in immunoglobulins, which lead to the subtypes IgA, IgE, and IgG play a central role. Honjo achieved worldwide recognition thanks to his discovery of a mechanism which acts to suppress the immune response. This opens the door to an approach to cancer therapy. For this achievement, Tasuku Honjo was awarded the 2018 Nobel Prize for Physiology or Medicine.
In some cancer cells, the immune response is suppressed. Tasuku Honjo was able to identify one of the proteins responsible for this effect, the immunoregulator PD1. By blocking this immunoregulator with specific monoclonal antibodies, so-called checkpoint inhibitors, the immune system is reactivated. On the basis of clinical studies in Japan and the United States, two such monoclonal antibodies were approved as medications in 2014. This triggers an immune response to the tumour tissue by the immune system.
Furthermore, Tasuku Honjo was able to uncover mechanisms, which lead to the maturation of B-lymphocytes.